文献速递前列腺癌泌尿系感染

雄激素剥夺治疗不降低前列腺癌患者SARS-CoV-2感染风险

Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
PubMed 文献 · J Urol · 2020-09-08

本研究基于前瞻性登记队列,纳入2020年3月12日至6月10日期间接受SARS-CoV-2检测的74787人,其中1779例前列腺癌患者。分析显示,使用雄激素剥夺治疗(ADT)与未使用者SARS-CoV-2阳性率分别为5.6%和5.8%,多因素分析未发现ADT与感染风险降低相关(OR 0.93,95%CI 0.54-1.61,p=0.8)。

要点

  • ADT使用与否的SARS-CoV-2阳性率无显著差异(5.6% vs 5.8%)。
  • 多因素分析未显示ADT降低感染风险(OR 0.93,95%CI 0.54-1.61)。
  • ADT使用者年龄更大且吸烟、使用类固醇比例更高。

核心结论

  • 雄激素剥夺治疗似乎不能预防SARS-CoV-2感染。

研究设计与样本

  • 前瞻性登记队列研究,纳入2020年3月12日至6月10日期间接受SARS-CoV-2检测的74787人,其中1779例前列腺癌患者。

主要发现

  • 前列腺癌患者中102例(5.7%)SARS-CoV-2阳性,304例(17.1%)使用ADT。
  • ADT使用者阳性率5.6%,非使用者5.8%。
  • ADT使用者年龄略大(75.5 vs 73.8岁,p=0.009),吸烟比例更高(68.1% vs 59.3%,p=0.005),使用类固醇比例更高(43.8% vs 23.3%,p<0.001)。
  • 多因素分析未显示ADT与感染风险差异相关(OR 0.93,95%CI 0.54-1.61,p=0.8)。

关键数值与推荐

  • ADT使用与SARS-CoV-2感染风险无显著关联(OR 0.93,95%CI 0.54-1.61,p=0.8)。

临床怎么用

  • 不应以预防SARS-CoV-2感染为目的对前列腺癌患者使用ADT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TMPRSS2 is a host co-receptor for cell entry of SARS-CoV-2. A prior report suggested that use of androgen deprivation therapy, which downregulates TMPRSS2, may protect men with prostate cancer from infection. MATERIALS AND METHODS: This is a cohort study of a prospective registry of all patients tested for SARS-CoV-2 between March 12 and June 10, 2020 with complete followup until disease recovery or death. The main exposure examined was the use of androgen deprivation therapy, and the outcome measures were the rate of SARS-CoV-2 positivity and disease severity as a function of androgen deprivation therapy use. RESULTS: The study cohort consisted of 1,779 men with prostate cancer from a total tested population of 74,787, of whom 4,885 (6.5%) were positive for SARS-CoV-2. Of those with prostate cancer 102 (5.7%) were SARS-CoV-2 positive and 304 (17.1%) were on androgen deprivation therapy. Among those on androgen deprivation therapy 5.6% were positive as compared to 5.8% not on androgen deprivation therapy. Men on androgen deprivation therapy were slightly older (75.5 vs 73.8 years, p=0.009), more likely to have smoked (68.1% vs 59.3%, p=0.005) and more likely to report taking steroids (43.8% vs 23.3%, p <0.001). Other factors known to increase risk of infection and disease severity were equally distributed (asthma, diabetes mellitus, hypertension, coronary artery disease, heart failure and immune suppressive disease). Multivariable analysis did not indicate a difference in infection risk for those with prostate cancer on androgen deprivation therapy (OR 0.93, 95% CI 0.54-1.61, p=0.8). CONCLUSIONS: Androgen deprivation therapy does not appear to be protective against SARS-CoV-2 infection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Klein EA, Li J, Milinovich A, et al. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. J Urol. 2020. PMID: 32897764. doi:10.1097/JU.0000000000001338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。